MoneyWorks4Me

Check Before You Invest : Aspira Pathlab & Diagnostics Ltd

BSE: 540788 NSE: ISIN: INE500C01017
  |   Sector:  Healthcare   |   Industry:  Hospital & Healthcare Services

Snapshot

Q.1 Which industry/sub-sector does Aspira Pathlab & Diagnostics Ltd belong to?
Aspira Pathlab & Diagnostics Ltd belongs to the Healthcare sector, operating specifically within the Hospital & Healthcare Services segment.
Q.2 Is Aspira Pathlab & Diagnostics Ltd a good quality company?
Aspira Pathlab & Diagnostics Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Aspira Pathlab & Diagnostics Ltd undervalued or overvalued?
Aspira Pathlab & Diagnostics Ltd appears Overvalued, as its key valuation ratios are higher than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios Current 0-year
Historic Median
Price to Earnings 55.79 34.95
Price to Book 10.59 8.23
Price to Sales 5.92 19.83
EV to EBITDA 30.2 25.02
Q.4 Is Aspira Pathlab & Diagnostics Ltd a good buy now?
Aspira Pathlab & Diagnostics Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

C: How much debt does the business have and is it at a sustainable level?

Q.1 Debt to Equity ratio of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd Debt-to-Equity ratio is 0.10, which is above the industry average of , indicating higher debt levels in the industry.

Q.2 Debt to cash flow from operations of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd Debt to cash flow from operations is 0.66, which is at a healthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Aspira Pathlab & Diagnostics Ltd?

Q.1 Promoter shareholding and pledge status of Aspira Pathlab & Diagnostics Ltd?
Promoters hold 46.58% of the Aspira Pathlab & Diagnostics Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Aspira Pathlab & Diagnostics Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Aspira Pathlab & Diagnostics Ltd vs industry peers?
Aspira Pathlab & Diagnostics Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Profit Metrics
Current Level 0-year
Industry Median
Revenue Growth (%) - -
Gross Profit Growth (%) 0 14.9
Operating Profit Growth (%) 0 15.3
Net Profit Growth (%) 0 15.7
Operating Efficiency
Current Level 0-year
Industry Median
Asset Turnover (x) 1.37 0.48
ROE (%) - 4.89
ROCE (%) - 7.53
Cash Conversion Cycle (days) 29.29 37

Valuation & price assessment

Q.1 Stock return of Aspira Pathlab & Diagnostics Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 11.56% based on the current price.
9Y 5Y 3Y 1Y
Share Price
CAGR
- 11.6% 52.2% 111.9%
Q.2 Valuation ratios of Aspira Pathlab & Diagnostics Ltd vs historical?
The current P/E ratio of 55.79 is higher than its historical median of 34.95, indicating that the stock is trading above its historical average valuation.
Q.3 How do the current valuation ratios compare with 0-year historical median and industry numbers?
Valuation Ratios Current 0-year
Historic Median
0-year
Industry Median
Price to Earnings 55.79 34.95 -
Price to Book 10.59 8.23 -
Price to Sales 5.92 19.83 -
EV to EBITDA 30.2 25.02 -

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: